NYSE$KVUE

Kenvue Inc · Q2 2026 earnings

Q2 2026 earnings · · Before market open · Investor relations

Briefing

Kenvue Inc reported third consecutive quarter of net and organic sales growth for Q2 2026.

Kenvue delivered net sales of $3.955 billion, up 3.0% year-over-year, with organic sales growth of 1.6%. Diluted EPS rose 9% to $0.24 while adjusted diluted EPS increased 7% to $0.31. Results met or exceeded plans across key metrics amid a pending merger with Kimberly-Clark.

  • Net sales grew 3.0% to $3.955 billion with organic sales up 1.6% across all segments and regions.
  • Diluted EPS increased 9% to $0.24 and adjusted diluted EPS rose 7% to $0.31.
  • Gross profit margin was 58.2% and adjusted gross profit margin was 60.2%, both down slightly year-over-year due to inflation and tariffs.
  • No forward guidance provided due to the pending Kimberly-Clark transaction expected to close in Q4 2026.

Headline financials

Total Revenue

$3.96B

Previous: $3.84B+3.0%
EPS (adj)

$0.31

Previous: $0.22+40.9%
Gross Profit Margin

58.2%

No prior period
Adjusted Gross Profit Margin

60.2%

No prior period
Operating Income Margin

17.7%

No prior period
Adjusted Operating Income Margin

22.1%

No prior period
Effective Tax Rate

23.7%

No prior period
Adjusted Effective Tax Rate

22.9%

No prior period
Research and Development Expenses

$94M

No prior period
Organic Revenue Growth

1.6%

No prior period
Organic Volume Growth

0.7%

No prior period
Organic Price/Mix Growth

0.9%

No prior period
Net Income

$456M

Previous: $420M+8.6%
Operating Income

$699M

Previous: $692M+1.0%
Gross Profit

$2.3B

Previous: $2.26B+1.8%
Cash & Equivalents

$1.1B

Previous: $1.07B+2.8%

Revenue & EPS history

Kenvue · Revenue · Quarterly

$3.96B

Q2 2026+3%vs Q2 2025
Beat estimate in 7 of 13 quarters(54%)
ActualEstimate

Revenue by segment

Kenvue · $3.96B total across 3 segments · Q2 2026

  • Self Care
    $1.59B
  • Essential Health
    $1.25B
  • Skin Health and Beauty
    $1.11B

Forward guidance

No forward-looking guidance provided due to pending transaction with Kimberly-Clark.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 13 quarterly earnings reports

Historical avg

+2.0%

Avg return

Earnings day

+3.1%

Avg return

5 days after

+2.8%

Avg return

30 days after

57%

8 / 14 earnings

Positive

+15.7%

Q3 2025

Best reaction

-7.7%

Q3 2023

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q2 2026
Q1 2026+2.0%-1.2%+0.2%
Q4 2025+0.9%+2.9%-5.5%
Q3 2025+15.7%+17.5%+18.1%
Q2 2025+1.5%+2.1%-13.2%
Q1 2025+4.3%+2.4%-6.0%
Q4 2024-4.5%+0.8%+12.9%
Q3 2024+5.2%+5.1%+1.5%
Q2 2024+13.4%+15.6%+23.7%
Q1 2024+7.2%+7.7%-2.4%
Q4 2022-0.2%+3.1%+12.9%
Q4 2023-5.8%-6.2%-2.4%
Q3 2023-7.7%-5.7%+2.6%
Q2 2023-4.0%+0.5%-8.5%
Q1 2023-0.5%-0.8%+4.5%
Q3 2022
Q2 2022
Q1 2022
Q4 2021

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro